Cipla Limited has said that it has entered into an exclusive marketing and distribution agreement with US-based MannKind Corporation for Afrezza® in India.
Afrezza® is the only USFDA approved inhaled insulin available for patients suffering from diabetes.
“Cipla is committed to providing access to innovative medicines and newer drug delivery systems to the patients. Afrezza, an inhaled insulin, is a cutting-edge product which will increase patient convenience,” said Umang Vohra, MD & Global CEO, Cipla Ltd.
“The innovative drug delivery system will revolutionize the diabetic care in India. This partnership with MannKind is another step from Cipla to cater to the unmet needs of the patients,” he added.
Under the agreement, Cipla will be responsible for obtaining regulatory approvals to distribute Afrezza® in India, including approval from the Drug Controller General of India (DCGI). Cipla will also be responsible for all marketing and sales activities of Afrezza in India. MannKind is responsible for supplying Afrezza to Cipla.
Meanwhile, shares of the company were trading at Rs 586.25 apiece, down 0.50 per cent from the previous close at 09:27 hours on BSE.